AAAAAA
Results: 1-25/31
Authors:
Millan, MJ
Newman-Tancredi, A
Quentric, Y
Cussac, D
Citation: Mj. Millan et al., The '' selective '' dopamine D-1 receptor antagonist, SCH23390, is a potent and high efficacy agonist at cloned human serotonin(2C) receptors, PSYCHOPHAR, 156(1), 2001, pp. 58-62
Authors:
Audinot, V
Newman-Tancredi, A
Cussac, D
Millan, MJ
Citation: V. Audinot et al., Inverse agonist properties of antipsychotic agents at cloned, human (h) serotonin (5-HT)(1B) and h5-HT1D receptors, NEUROPSYCH, 25(3), 2001, pp. 410-422
Authors:
Audinot, V
Newman-Tancredi, A
Millan, MJ
Citation: V. Audinot et al., Constitutive activity at serotonin 5-HT1D receptors: detection by homologous GTP gamma S versus [S-35]-GTP gamma S binding isotherms, NEUROPHARM, 40(1), 2001, pp. 57-64
Authors:
Newman-Tancredi, A
Chaput, C
Touzard, M
Millan, MJ
Citation: A. Newman-tancredi et al., Pindolol antagonises G-protein activation at both pre- and postsynaptic serotonin 5-HT1A receptors: a [S-35]GTP gamma S autoradiography study, N-S ARCH PH, 363(4), 2001, pp. 391-398
Authors:
Millan, MJ
Gobert, A
Lejeune, F
Newman-Tancredi, A
Rivet, JM
Auclair, A
Peglion, JL
Citation: Mj. Millan et al., S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine, J PHARM EXP, 298(2), 2001, pp. 565-580
Authors:
Millan, MJ
Cussac, D
Milligan, G
Carr, C
Audinot, V
Gobert, A
Lejeune, F
Rivet, JM
Brocco, M
Duqueyroix, D
Nicolas, JP
Boutin, JA
Newman-Tancredi, A
Citation: Mj. Millan et al., Antiparkinsonian agent piribedil displays antagonist properties at native,rat, and cloned, human alpha(2)-adrenoceptors: Cellular and functional characterization, J PHARM EXP, 297(3), 2001, pp. 876-887
Authors:
Cordi, AA
Berque-Bestel, I
Persigand, T
Lacoste, JM
Newman-Tancredi, A
Audinot, V
Millan, MJ
Citation: Aa. Cordi et al., Potential antidepressants displayed combined alpha(2)-adrenoceptor antagonist and monoamine uptake inhibitor properties, J MED CHEM, 44(5), 2001, pp. 787-805
Authors:
Newman-Tancredi, A
Verriele, L
Touzard, M
Millan, MJ
Citation: A. Newman-tancredi et al., Efficacy of antipsychotic agents at human 5-HT1A receptors determined by [H-3]WAY100,635 binding affinity ratios: Relationship to efficacy for G-protein activation, EUR J PHARM, 428(2), 2001, pp. 177-184
Authors:
Millan, MJ
Newman-Tancredi, A
Duqueyroix, D
Cussac, D
Citation: Mj. Millan et al., Agonist properties of pindolol at h5-HT1A receptors coupled to mitogen-activated protein kinase, EUR J PHARM, 424(1), 2001, pp. 13-17
Authors:
Newman-Tancredi, A
Verriele, L
Millan, MJ
Citation: A. Newman-tancredi et al., Differential modulation by GTP gamma S of agonist and inverse agonist binding to h5-HT1A receptors revealed by [H-3]-WAY100,635, BR J PHARM, 132(2), 2001, pp. 518-524
Authors:
Millan, MJ
Gobert, A
Rivet, JM
Adhumeau-Auclair, A
Cussac, D
Newman-Tancredi, A
Dekeyne, A
Nicolas, JP
Lejeune, F
Citation: Mj. Millan et al., Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha(2)-adrenergic and serotonin(2C) receptors: a comparison with citalopram, EUR J NEURO, 12(3), 2000, pp. 1079-1095
Authors:
Gobert, A
Rivet, JM
Lejeune, F
Newman-Tancredi, A
Adhumeau-Auclair, A
Nicolas, JP
Cistarelli, L
Melon, C
Millan, MJ
Citation: A. Gobert et al., Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat, SYNAPSE, 36(3), 2000, pp. 205-221
Authors:
Millan, MJ
Newman-Tancredi, A
Audinot, V
Cussac, D
Lejeune, F
Nicolas, JP
Coge, F
Galizzi, JP
Boutin, JA
Rivet, JM
Dekeyne, A
Gobert, A
Citation: Mj. Millan et al., Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT1B, 5-HT1D and dopamine D-2 and D-3 receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states, SYNAPSE, 35(2), 2000, pp. 79-95
Authors:
Morris, BJ
Newman-Tancredi, A
Audinot, V
Simpson, CS
Millan, MJ
Citation: Bj. Morris et al., Activation of dopamine D-3 receptors induces c-fos expression in primary cultures of rat striatal neurons, J NEUROSC R, 59(6), 2000, pp. 740-749
Authors:
Newman-Tancredi, A
Chaput, C
Touzard, M
Millan, MJ
Citation: A. Newman-tancredi et al., [S-35]-GTP gamma S autoradiography reveals alpha(2) adenoceptor-mediated G-protein activation in amygdala and lateral septum, NEUROPHARM, 39(6), 2000, pp. 1111-1113
Authors:
Cussac, D
Newman-Tancredi, A
Nicolas, JP
Boutin, JA
Millan, MJ
Citation: D. Cussac et al., Antagonist properties of the novel antipsychotic, S16924, at cloned, humanserotonin 5-HT2C receptors: a parallel phosphatidylinositol and calcium accumulation comparison with clozapine and haloperidol, N-S ARCH PH, 361(5), 2000, pp. 549-554
Authors:
Cussac, D
Newman-Tancredi, A
Sezgin, L
Millan, MJ
Citation: D. Cussac et al., [H-3]S33084: a novel, selective and potent radioligand at cloned, human dopamine D-3 receptors, N-S ARCH PH, 361(5), 2000, pp. 569-572
Authors:
Cussac, D
Newman-Tancredi, A
Quentric, Y
Millan, MJ
Citation: D. Cussac et al., An innovative method for rapid characterisation of phospholipase C activity: SB242,084 competitively antagonises 5-HT2C receptor-mediated [H-3]phosphatidylinositol depletion, N-S ARCH PH, 361(2), 2000, pp. 221-223
Authors:
Newman-Tancredi, A
Audinot, V
Moreira, C
Verriele, L
Millan, MJ
Citation: A. Newman-tancredi et al., Inverse agonism and constitutive activity as functional correlates of serotonin h5-HT1B receptor/G-protein stoichiometry, MOLEC PHARM, 58(5), 2000, pp. 1042-1049
Authors:
Millan, MJ
Dekeyne, A
Newman-Tancredi, A
Cussac, D
Audinot, V
Milligan, G
Duqueyroix, D
Girardon, S
Mullot, J
Boutin, JA
Nicolas, JP
Renouard-Try, A
Lacoste, JM
Cordi, A
Citation: Mj. Millan et al., S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine, J PHARM EXP, 295(3), 2000, pp. 1192-1205
Authors:
Millan, MJ
Gobert, A
Newman-Tancredi, A
Lejeune, F
Cussac, D
Rivet, JM
Audinot, V
Dubuffet, T
Lavielle, G
Citation: Mj. Millan et al., S33084, a novel, potent, selective, and competitive antagonist at dopamineD-3-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626, J PHARM EXP, 293(3), 2000, pp. 1048-1062
Authors:
Millan, MJ
Gobert, A
Newman-Tancredi, A
Lejeune, F
Cussac, D
Rivet, JM
Audinot, V
Adhumeau, A
Brocco, M
Nicolas, JP
Boutin, JA
Despaux, N
Peglion, JL
Citation: Mj. Millan et al., S18327 (1-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperid-1-yl]ethyl}3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1) and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile, J PHARM EXP, 292(1), 2000, pp. 38-53
Authors:
Millan, MJ
Brocco, M
Rivet, JM
Audinot, V
Newman-Tancredi, A
Maiofiss, L
Queriaux, S
Despaux, N
Peglion, JL
Dekeyne, A
Citation: Mj. Millan et al., S18327 (1-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperid-1-yl]ethyl}3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1) and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine,and 11 other antipsychotic agents, J PHARM EXP, 292(1), 2000, pp. 54-66
Authors:
Cussac, D
Newman-Tancredi, A
Sezgin, L
Millan, MJ
Citation: D. Cussac et al., The novel antagonist, S33084, and CR218,231 interact selectively with cloned and native, rat dopamine D-3 receptors as compared with native, rat dopamine D-2 receptors, EUR J PHARM, 394(1), 2000, pp. 47-50
Authors:
Dubuffet, T
Newman-Tancredi, A
Cussac, D
Audinot, V
Loutz, A
Millan, MJ
Lavielle, G
Citation: T. Dubuffet et al., Novel benzopyrano[3,4-c]pyrrole derivatives as potent and selective dopamine D-3 receptor antagonists, BIOORG MED, 9(14), 1999, pp. 2059-2064